CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma (“Be Bio”), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM), today announced the closing of a $130 million financing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results